Marc Ferrer,
Director, 3D Tissue Model Laboratory,
NIH/NCATS
Marc Ferrer is currently the director of the 3D tissue model laboratory at NCATS. He graduated with a BSc degree in Organic Chemistry from the University of Barcelona, Spain, in 1989, and received his Ph.D. degree in Biological Chemistry from the University of Minnesota, in 1994. He was a postdoctoral fellow at Harvard University from 1995-1999, where he used structure-based chemical approaches for the development of anti-HIV small molecules. He joined the Department of Automated Biotechnology at the Merck Research Laboratories in 1999, where he became Director of Assay Development and High Throughput Screening. In 2010, he joined the NIH Chemical Genomics Center where he worked with investigators in the academic community to implement high throughput screening and medicinal chemistry programs for the discovery of small molecule probes to study protein function in vitro and in animal models of diseases. In the last four years, he has led the implementation of a 3D Tissue Model Laboratory at NCATS, a multidisciplinary group that uses 3D tissue biofabrication techniques, including 3D Bioprinting, to create assay models of human live tissues in multi-well plate format for drug discovery. Dr. Ferrer has co-authored more than 120 peer-reviewed scientific publications.
Biofabrication of 3D Tissue Models For Disease Modeling and Drug Screening
Monday, 14 October 2019 at 16:30
Add to Calendar ▼2019-10-14 16:30:002019-10-14 17:30:00Europe/LondonBiofabrication of 3D Tissue Models For Disease Modeling and Drug ScreeningThe Space Summit 2019 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com
Biofabrication of architecturally defined and physiologically relevant human tissues is emerging as a key technology for drug discovery. The expectation is that 3D biofabricated tissues produced with human iPSC-derived cells will provide functionally and physiologically relevant assay platforms to test small molecules during drug discovery and help narrow the current gaps between current simplistic in-vitro cell assays, non-predictive in-vivo animal models, and human clinical trials. Tissue biofabrication integrates advances in tissue engineering technologies and cell biology, with the development of three-dimensional (3D) bioprinters, biocompatible polymers and hydrogels, and methods to validate the morphology and function of human tissues. I will be presenting some of the work on going at the 3D Tissue Model Laboratory at NCATS to implement rapid, scalable, and reliable biofabrication of architecturally and physiologically defined functional human tissue models in multiwell-plate platforms for disease modeling and drug screening.
Add to Calendar ▼2019-10-14 00:00:002019-10-15 00:00:00Europe/LondonThe Space Summit 2019The Space Summit 2019 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2019-10-14 16:30:002019-10-14 17:30:00Europe/LondonBiofabrication of 3D Tissue Models For Disease Modeling and Drug ScreeningThe Space Summit 2019 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com
.jpg)
